GLP-1 Receptor Agonists and Egg Freezing
Yes, you can undergo oocyte cryopreservation (egg freezing) while on a GLP-1 receptor agonist, but you should ideally discontinue the medication before starting ovarian stimulation to optimize outcomes and avoid potential interference with the fertility preservation protocol.
Primary Recommendation
Discontinue GLP-1 receptor agonists before initiating ovarian stimulation for egg freezing. While no direct contraindication exists in fertility preservation guidelines, GLP-1 receptor agonists can cause gastrointestinal side effects (nausea, vomiting, delayed gastric emptying) that may complicate the ovarian stimulation process and potentially affect nutritional status during a metabolically demanding procedure 1, 2.
The timing of discontinuation should account for the medication's half-life: short-acting agents like exenatide can be stopped 1-2 days before stimulation, while long-acting agents like semaglutide or dulaglutide require 4-5 weeks for complete clearance 3.
Rationale for Temporary Discontinuation
Nutritional Considerations
GLP-1 receptor agonists are associated with micronutrient deficiencies including vitamin D (13.6% at 12 months), iron depletion (26-30% lower ferritin), and inadequate calcium intake (>60% of users consume below requirements) 3.
Ovarian stimulation is a metabolically demanding process requiring optimal nutritional status, and pre-existing deficiencies may theoretically impact oocyte quality, though this has not been directly studied 4, 5.
Gastrointestinal Effects
The most common adverse events with GLP-1 receptor agonists are mild-to-moderate gastrointestinal symptoms (nausea, vomiting, delayed gastric emptying), occurring predominantly during dose escalation 6.
These symptoms could interfere with the ability to tolerate the hormonal medications required for ovarian stimulation and may complicate monitoring during the 10-14 day stimulation protocol 2, 4.
Ovarian Stimulation Protocol Considerations
Standard Timeline
When ≥2 weeks are available, ovarian stimulation followed by oocyte cryopreservation is the preferred approach 2.
Random-start protocols permit initiation at any point in the menstrual cycle, typically requiring 10-14 days of gonadotropin injections before oocyte retrieval 2.
Age-Specific Targets
For patients ≤35 years, aim to retrieve approximately 12 oocytes (associated with ~62% cumulative live-birth rate) 2.
For patients 36-40 years, aim to retrieve approximately 10 oocytes (associated with ~43% cumulative live-birth rate) 2.
If initial retrieval yields insufficient oocytes, double stimulation (two consecutive cycles within ~4 weeks) can roughly double the oocyte yield 2.
Clinical Algorithm
Assess urgency: Determine if egg freezing is time-sensitive (e.g., before cancer treatment) or elective 1, 2.
Discontinue GLP-1 receptor agonist:
Optimize nutritional status: Check vitamin D, iron, and calcium levels; supplement as needed during the washout period 3.
Initiate ovarian stimulation: Use standard or random-start protocols with gonadotropins, with or without letrozole if estrogen-sensitive concerns exist 1, 2.
Resume GLP-1 receptor agonist: Restart medication after oocyte retrieval once gastrointestinal symptoms from anesthesia have resolved, typically 1-2 weeks post-procedure 6.
Important Caveats
No direct evidence exists examining the interaction between GLP-1 receptor agonists and ovarian stimulation outcomes, so this recommendation is based on the known pharmacology and side-effect profile of these medications 7, 3, 6.
If discontinuation poses significant metabolic risk (e.g., poorly controlled diabetes), discuss with both the reproductive endocrinologist and endocrinologist to weigh risks versus benefits on a case-by-case basis 7, 6.
The fertility preservation process itself (ovarian stimulation and retrieval) does not adversely impact oncologic outcomes or overall survival, even in patients with hormone-sensitive cancers 1, 2.